News
04-15-2010, 06:15 PM
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products, today announced that Roche has provided a favorable update related to its plans to apply for marketing approval of trastuzumab-DM1 (T-DM1) in the US...
More... (http://mnt.to/f/3Bjb)
More... (http://mnt.to/f/3Bjb)